GLP-1 News — Week of June 1, 2026
The GLP-1 stories that mattered this week — each one summarised neutrally and linked to its primary source. Nothing here is influenced by advertisers.
Cigna will end coverage of GLP-1 weight-loss drugs for its own employees
Cigna notified its employees that its internal health plan will stop covering GLP-1 medications used for weight loss, including Wegovy and Zepbound, effective 2026-07-01, while continuing coverage for diabetes and other non-obesity indications. The move illustrates how employer plans can change obesity-drug coverage mid-year and underscores the importance of checking indication-specific benefits, appeal rights, and alternative qualifying diagnoses when clinically appropriate. (2026-06-02)
Source: Investing.com (via Reuters)
Related on Metabolic Ledger: /cost/insurance-coverage-glp1
CVS Caremark to add Zepbound back as a preferred option from October 1, 2026
CVS Caremark announced on May 28, 2026 that it will add Lilly's Zepbound back to its commercial formularies "as an additional preferred option" on October 1, 2026, and that from June 1, 2026 it will remove its new-to-market block on Lilly's oral Foundayo where plans approve coverage (CVS Health). Wegovy, which Caremark made its preferred weight-loss GLP-1 in July 2025, keeps its place; the change adds choice rather than removing it. For patients on CVS-managed plans, what is covered still depends on each employer's or insurer's own benefit design, prior-authorization rules and cost sharing.
Correction, September 29, 2026: an earlier version of this item said Zepbound and Foundayo already shared preferred status with Wegovy. Zepbound's return takes effect on October 1, 2026.
Source: CVS Health, May 28, 2026
Related on Metabolic Ledger: /drugs/best-glp1-for-weight-loss
GLP-1 coverage changes across major PBMs position Lilly's obesity drugs for broad access
A Sina Finance report said that by early June 2026 Lilly's Zepbound and oral Foundayo had coverage agreements with all three major U.S. PBMs: Express Scripts, Optum Rx and CVS Caremark. CVS's own announcement puts Zepbound's return to its formularies on October 1, 2026, not June, so for CVS-managed plans the change is still to come. Patient-level access continues to depend on each employer's or insurer's benefit design, prior-authorization rules and cost sharing. (2026-06-07; corrected September 29, 2026)
Source: Sina Finance
Related on Metabolic Ledger: /cost/insurance-coverage-glp1
Phase 2b trial shows promising weight loss with once-daily oral small-molecule GLP-1 agonist aleniglipron
A phase 2b randomized, double-blind, placebo-controlled trial in Nature Medicine found that the oral small-molecule GLP-1 receptor agonist aleniglipron produced clinically meaningful weight loss in adults with overweight or obesity. The findings add to a growing pipeline of non-injectable obesity therapies and suggest that future options may broaden beyond current peptide-based oral and injectable GLP-1 drugs. (2026-06-05)
Source: Nature Medicine
Phase 3 REDEFINE 5 trial finds cagrilintide plus semaglutide superior to semaglutide alone for weight loss in East Asian adults
The REDEFINE 5 phase 3a trial in Japan and Taiwan showed that combining cagrilintide with semaglutide led to greater weight loss than semaglutide alone in adults with overweight or obesity, with or without type 2 diabetes, while maintaining an acceptable safety profile. These results support the potential of future fixed-dose combination injectables to extend efficacy beyond current GLP-1 monotherapies, pending regulatory review and broader availability. (2026-06-01)
Source: The Lancet Diabetes & Endocrinology
Related on Metabolic Ledger: /drugs/cagrisema
Analysis highlights how GLP-1 drug race is shifting toward long-term maintenance, convenience, and affordability
Axios reports that as GLP-1 and related obesity drugs show large early weight-loss effects, manufacturers are increasingly focused on maintaining weight loss, improving tolerability, and simplifying dosing through combinations and longer-acting agents. The piece emphasizes that future competition and coverage debates are likely to center on long-term adherence, cost, and matching individual patients to sustainable regimens rather than short-term weight reduction alone. (2026-06-03)
Source: Axios
Related on Metabolic Ledger: /after-glp1/glp1-maintenance-dose